Sarepta Stock Jumps on Expanded FDA Approval for Duchenne Muscular Dystrophy Gene Therapy
Updated results show the biotech's RAS inhibitor shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.
Lexeo Therapeutics stock crashed Monday despite promising results for a gene therapy designed to treat heart problems of a genetic condition.
Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.
What if there was a way to peer into your body and spot early signs of cancer and other life-threatening ailments before they became serious? Startup companies like Prenuvo charge between $1,000 to $2,500 for various scanning options, none of which are currently covered by insurance. The industry has received a big publicity push from celebrities and influencers like Kim Kardashian, who posted about her Prenuvo scan last year.
A new study raises important implications regarding the competitive balance between these two companies.
AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.
The Phase I trial will involve 20 hospitals across China and will establish the recommended Phase II dose.
